RxDoctor Payments Data

Vasanth Sathiyakumar, MD

Cardiovascular Disease · Canton, GANPI 1154716082

Payments from drug & device makers

$19,975in general payments, 2019–2025

Across 258 payments — averaging $77.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$14K
  • Novartis$2K
  • Novo Nordisk$620
  • E.r. Squibb & Sons, L.L.C.$437
  • Merck$410
  • Heartflow, Inc.$228
  • plus $2K from 23 others

What the payments were for

  • Consulting fees$8,72844%
  • Speaking & faculty fees$5,60028%
  • Travel & lodging$200%
  • Food & beverage$5,62828%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,975 in reported general payments places this provider in the 85th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$593,178
Medicare patients
2,525
Services billed
13,984

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban194$246,749
EntrestoSacubitril/Valsartan78$106,128
XareltoRivaroxaban55$75,298
FarxigaDapagliflozin Propanediol16$21,464
JardianceEmpagliflozin14$21,175
Repatha SureclickEvolocumab15$19,640
Metoprolol Succinate347$4,722
Atorvastatin Calcium399$3,418
Rosuvastatin Calcium197$2,633
Ezetimibe103$2,092
Diltiazem 24hr Er (La)Diltiazem Hcl15$1,649
Losartan Potassium135$1,402
Flecainide Acetate19$1,175
Amlodipine Besylate132$1,136
Carvedilol109$999

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$204$246,749194 claims
NovartisEntresto$2,405$106,12878 claims
Johnson & JohnsonXarelto$85$75,29855 claims
AstraZenecaFarxiga$118$21,46416 claims
Boehringer IngelheimJardiance$57$21,17514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Canton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →